Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Sillesen H, Amarenco P, Hennerici MG, Callahan A, Goldstein LB, Zivin J, Messig M, Welch KM; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Sillesen H, et al. Among authors: goldstein lb. Stroke. 2008 Dec;39(12):3297-302. doi: 10.1161/STROKEAHA.108.516450. Epub 2008 Oct 9. Stroke. 2008. PMID: 18845807
Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A 3rd, Hennerici M, Simunovic L, Zivin JA, Welch KM; SPARCL Investigators. Amarenco P, et al. Among authors: goldstein lb. Stroke. 2007 Dec;38(12):3198-204. doi: 10.1161/STROKEAHA.107.493106. Epub 2007 Oct 25. Stroke. 2007. PMID: 17962589 Clinical Trial.
Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
Goldstein LB, Amarenco P, Lamonte M, Gilbert S, Messig M, Callahan A, Hennerici M, Sillesen H, Welch KM; SPARCL Investigators. Goldstein LB, et al. Stroke. 2008 Sep;39(9):2444-8. doi: 10.1161/STROKEAHA.107.513747. Epub 2008 Jul 10. Stroke. 2008. PMID: 18617654 Clinical Trial.
Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Amarenco P, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, O'Neill BJ, Rudolph AE, Simunovic L, Zivin JA, Welch KM; SPARCL Investigators. Amarenco P, et al. Among authors: goldstein lb. Atherosclerosis. 2009 Jun;204(2):515-20. doi: 10.1016/j.atherosclerosis.2008.09.008. Epub 2008 Sep 18. Atherosclerosis. 2009. PMID: 18962621 Clinical Trial.
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes.
Amarenco P, Benavente O, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, Gilbert S, Rudolph AE, Simunovic L, Zivin JA, Welch KM; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Amarenco P, et al. Among authors: goldstein lb. Stroke. 2009 Apr;40(4):1405-9. doi: 10.1161/STROKEAHA.108.534107. Epub 2009 Feb 19. Stroke. 2009. PMID: 19228842 Clinical Trial.
Prevention and health services delivery.
Goldstein LB, Amarenco P. Goldstein LB, et al. Stroke. 2004 Feb;35(2):401-3. doi: 10.1161/01.STR.0000115534.96846.66. Stroke. 2004. PMID: 14757892 No abstract available.
Prevention and health services delivery.
Goldstein LB, Amarenco P. Goldstein LB, et al. Stroke. 2005 Feb;36(2):222-4. doi: 10.1161/01.STR.0000153050.27021.b1. Epub 2005 Jan 6. Stroke. 2005. PMID: 15637322 Review. No abstract available.
408 results